ArticleBMC cancer2025
Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis investigation delineates the differential impact of recurrence patterns-specifically, anastomotic recurrence (AR) and lymph node recurrence (LNR)-on the survival outcomes of patients with esophageal squamous cell carcinoma (ESCC). Additionally, it assesses the therapeutic efficacy of adjuvant radiotherapy in modifying these postoperative recurrence dynamics to inform optimized clinical management. METHODS AND MATERIALS: A retrospective cohort analysis was conducted on 434 patients who developed recurrent ESCC following radical surgery at Shandong Cancer Hospital, from July 2018 through December 2022. Comprehensive clinical data were analyzed using logistic and Cox proportional hazards regression models to elucidate the risk factors associated with AR and LNR.
resultsOf the patients analyzed, 118 exhibited AR post-surgery. Multivariate logistic regression identified advanced N stage and the presence of LNR as predominant risk factors influencing recurrence. Survival analysis, employing Kaplan-Meier estimates, demonstrated a median survival time (MST) of 21 months (range: 1.6-146.1 months) for patients with AR. In patients experiencing LNR, Cox regression analyses revealed tumor location and the application of adjuvant radiotherapy as critical determinants of survival outcomes. Significantly, adjuvant radiotherapy markedly reduced the incidence of LNR, thereby attenuating overall recurrence rates.
conclusionsPostoperative recurrence significantly compromises survival in ESCC, underscoring the critical need for precise risk stratification and proactive management. This study substantiates the prognostic significance of adjuvant radiotherapy in reducing recurrence, providing pivotal insights for tailoring treatment protocols to enhance patient prognoses in ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.